Patents by Inventor Edward J. Rebar

Edward J. Rebar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED TARGET SPECIFIC NUCLEASES
    Publication number: 20240132917
    Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 25, 2024
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • Compositions for linking DNA-binding domains and cleavage domains
    Patent number: 11920169
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases with alternative configurations. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: March 5, 2024
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar
  • Methods and compositions for the treatment of lysosomal storage diseases
    Patent number: 11898158
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: February 13, 2024
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Methods and compositions for regulation of transgene expression
    Patent number: 11859190
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: January 2, 2024
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20230414710
    Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
    Type: Application
    Filed: June 29, 2023
    Publication date: December 28, 2023
    Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
  • METHODS AND COMPOSITIONS FOR TREATMENT OF A GENETIC CONDITION
    Publication number: 20230416775
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Application
    Filed: November 7, 2022
    Publication date: December 28, 2023
    Inventors: Gregory J. Cost, Dmitry Guschin, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • Regulation of gene expression using engineered nucleases
    Patent number: 11845965
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: December 19, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • Engineered target specific nucleases
    Patent number: 11827900
    Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 28, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • TARGETED DISRUPTION OF T CELL AND/OR HLA RECEPTORS
    Publication number: 20230295563
    Abstract: Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Application
    Filed: October 21, 2022
    Publication date: September 21, 2023
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, David Paschon, Edward J. Rebar, Lei Zhang
  • Methods and compositions for treating Huntington's Disease
    Patent number: 11723952
    Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: August 15, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
  • DNA-binding proteins and uses thereof
    Patent number: 11661612
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: May 30, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
  • Methods and compositions for regulation of transgene expression
    Patent number: 11639504
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: May 2, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Methods and compositions for treating hemophilia
    Patent number: 11634463
    Abstract: Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins involved in clotting into the genome of a cell for treating conditions including hemophilias.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: April 25, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar
  • Targeted disruption of T cell and/or HLA receptors
    Patent number: 11512287
    Abstract: Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 29, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, David Paschon, Edward J. Rebar, Lei Zhang
  • DNA-BINDING PROTEINS AND USES THEREOF
    Publication number: 20220356493
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Application
    Filed: June 11, 2021
    Publication date: November 10, 2022
    Inventors: Philip D. GREGORY, Jeffrey C. MILLER, David PASCHON, Edward J. REBAR, Siyuan TAN, Fyodor URNOV, Lei ZHANG
  • Methods and compositions for treatment of a genetic condition
    Patent number: 11492643
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: November 8, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • METHODS OF TREATING LYSOSOMAL STORAGE DISEASES
    Publication number: 20220331447
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for the provision of proteins lacking or deficient in subjects with a lysosomal storage disease and treatment and/or prevention of lysosomal storage diseases.
    Type: Application
    Filed: November 22, 2021
    Publication date: October 20, 2022
    Inventor: Edward J. Rebar
  • Zinc finger protein compositions for modulation of huntingtin (Htt)
    Patent number: 11421007
    Abstract: The present disclosure is in the field of modulation of Htt gene expression and HTT protein levels.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: August 23, 2022
    Assignees: Sangamo Therapeutics, Inc., CHDI Foundation, Inc.
    Inventors: Steven Froelich, Ignacio Munoz-Sanjuan, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • Zinc finger protein compositions for modulation of huntingtin (Htt)
    Patent number: 11279739
    Abstract: The present disclosure is in the field of modulation of Htt gene expression and HTT protein levels.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: March 22, 2022
    Assignees: Sangamo Therapeutics, Inc., CHDI Foundation, Inc.
    Inventors: Steven Froelich, Ignacio Munoz-Sanjuan, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • HTT REPRESSORS AND USES THEREOF
    Publication number: 20210369872
    Abstract: Disclosed herein are Htt repressors and methods and compositions for use of these Htt repressors.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 2, 2021
    Inventors: Steven Froelich, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang